CORT

Corcept Therapeutics Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California.

Did you know?

Generated $672.0 in free cash flow for every $1 of capital expenditure in FY25.

Current Price

$51.42

+10.53%

GoodMoat Value

$16.61

67.7% overvalued

Profile

Valuation (TTM)

Market Cap$5.47B

P/E117.20

EV—

P/B8.44

Shares Out106.37M

P/Sales7.11

Revenue$769.10M

EV/EBITDA—

Corcept Therapeutics Inc (CORT) Dividends

Dividend Overview

Dividend Yield

—

Dividend / Share

—

Key Metrics

Market Cap

$5.47B

P/E Ratio

117.20

Forward P/E

—

EPS

$0.82

PEG Ratio

-0.45

Book Value

$6.09

Dividend Yield

—

Profit Margin

6.07%

ROE

7.20%

Dividend History

Dividend Safety

CORT Dividend Analysis

Corcept Therapeutics Inc (CORT) dividend analysis including yield, payout history, and sustainability metrics.

P/E ratio: 117.20. Profit margin: 6.07%. Free cash flow: $141.78M. This page shows Corcept Therapeutics Inc's dividend overview, key metrics, historical payout data, and dividend safety assessment to help income-focused investors evaluate the sustainability of dividend payments.

GoodMoat's dividend analyzer evaluates payout ratios, earnings coverage, and free cash flow coverage to determine how well supported Corcept Therapeutics Inc's dividend payments are. Use this analysis alongside the company's financial statements and quality score to make informed income-investing decisions.